Terminated PHASE2 INTERVENTIONAL 1-arm NCT02179567

Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC

First Line Treatment of Elderly Patients With Advanced or Metastatic NSCLC With Docetaxel and Bevacizumab

Sponsor: Hellenic Oncology Research Group

Conditions NSCLC

Updated 5 times since 2017 Last updated: Sep 25, 2015 Started: Mar 31, 2010 Primary completion: Mar 31, 2013 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Terminated due to poor accrual

Other terminated trials from Hellenic Oncology Research Group

More terminations from Hellenic Oncology Research Group

Other NSCLC trials with similar outcome

Browse all NSCLC trials

A PHASE2 clinical study on NSCLC, this trial is terminated or withdrawn. The trial is conducted by Hellenic Oncology Research Group and has accumulated 5 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hellenic Oncology Research Group

Data source: Hellenic Oncology Research Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Athens, Greece
• Heraklion, Greece